Clearwater International acted as sole financial adviser to Merz GmbH & Co. KGaA on the sale of Senator GmbH & Co. KGaA to Perusa Partners.
Senator, founded in 1920 and headquartered in Gross-Bieberau, is a worldwide leading manufacturer of customised and individualised writing instruments and promotional products. In 2014-2015 the company generated revenues of approx. €50m with over 350 employees. Beside high-quality writing instruments, the product range also comprises drinkware, writing cases and accessories.
Independent private equity firm Perusa Partners, was established in 2008 and is currently investing through two funds with equity of €350m. Its primary focus is in medium-sized businesses from corporate groups, with potential for long-term value creation based in German-speaking or Scandinavian countries.
With more than 2,900 employees and 36 subsidiaries, Merz is a leading global provider in the fields of aesthetics and neurotoxins. Privately held for more than 100 years, the company is distinguished by its in-house research and development, solid financial strength and continuous growth. Complementing its unique portfolio of products for minimally invasive and non-invasive skin rejuvenation and tightening, Merz also develops neurotoxins to treat neurologically induced movement disorders. Over-the-counter medicines, dietary supplements and skincare products round off the offerings from the company, which is headquartered in Frankfurt, Germany. In 2014-2015 the Merz Pharma Group generated revenue of €1,157m.
Clearwater International advised Merz, led by partner Ralph Schmücking, with support from associate Eduard Miller and analyst Daniel Stratenhoff.
Ralph Schmücking, Partner, Clearwater International said: “We are delighted to have assisted the Merz Group on another strategic project that reflects the clear focussing of its activities in the areas of aesthetics, neurotoxins and consumer care.”